Clinical Trial Update: Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Isovorin (leucovorin) in advanced or recurrent gastric cancer has completed; sponsor Wyeth, now part of Pfizer, conducted the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Isovorin (Leucovorin)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Gastric Cancer | Phase 3 | Status: COMPLETED